MARKETING ANALYSIS OF MEDICINAL PRODUCTS FOR THE TREATMENT OF SLEEP DISORDERS IN MILITARY PERSONNEL WITH MILD TRAUMATIC BRAIN INJURY CAUSED BY BLAST EXPOSURE

Abstract

Sleep disorders are a prevalent consequence of mild traumatic brain injury (TBI) in military personnel caused by blast exposure, significantly impairing quality of life and functional capacity. Treatment requires a multifaceted approach, including cognitive-behavioral therapy, normalization of sleep hygiene, and pharmacotherapy. Market analysis of medicinal products enables optimization of therapeutic strategies for effective sleep disorder management and identification of directions for further development of domestic drug production.The aim of the study was to conduct a marketing analysis of medicinal products registered in the Ukrainian pharmaceutical market used for the treatment of sleep disorders in military personnel who suffered mild traumatic brain injury following blast exposure.A comprehensive methodology was applied, including the analysis of clinical and methodological guidelines, data from the State Register of Medicinal Products of Ukraine as of April 2025, and information from aggregator resources such as “Drug Reference Guide Compendium” and Tabletki.ua. Informational, comparative, analytical, and marketing analysis methods were applied, with subsequent generalization and systematization of the obtained data.The analysis of clinical-methodological guidelines revealed discrepancies in the nomenclature of recommended medicinal products between international and national protocols, attributed to the absence of state registration in Ukraine for certain medications (e.g., prazosin, zolpidem, ramelteon, suvorexant). As of April 2025, the Ukrainian pharmaceutical market includes 34 trade names of medicinal products for treating sleep disorders in military personnel with mild TBI, comprising 11 psycholeptic drugs (predominantly subgroup N05CF, with zopiclone accounting for 20.59 %) and 23 psychoanaleptic drugs (dominated by subgroup N06AX, with mirtazapine constituting 23.52 %).A significant portion (64.7 %) of the analysed drugs are imported, with Poland leading in psycholeptics and Slovenia in psychoanaleptics. Domestic products account for 35.3 % of the total assortment. Psycholeptic drugs are available only in oral dosage forms, while psychoanaleptics offer a wider range, including various tablet forms, capsules, and injectable solutions.The Ukrainian pharmaceutical market of has a limited range of medicines for the treatment of sleep disorders and shows substantial dependence on imported products, especially in the psychoanaleptic segment. The limited dosage form diversity among domestic products may hinder individualized therapy. To enhance pharmacotherapeutic provision for this patient group, should focus on fostering domestic production to expand the range of available medicinal products and diversify the forms of domestic psycholeptics.